Published in Gut on March 17, 2006
Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol (2012) 2.97
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
The human intestinal microbiome: a new frontier of human biology. DNA Res (2009) 2.30
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta (2011) 1.60
PPARgamma in human and mouse physiology. Biochim Biophys Acta (2007) 1.58
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.50
Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer. J Bacteriol (2008) 1.41
Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells. Proc Natl Acad Sci U S A (2008) 1.38
Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep (2012) 1.37
Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat Med (2010) 1.36
Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26
Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol (2006) 1.25
Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med (2006) 1.19
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol (2010) 1.10
The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol (2007) 1.06
Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med (2009) 1.04
Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut (2006) 1.03
Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J Pharmacol Exp Ther (2013) 1.02
Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ. Mol Cell Biol (2013) 0.99
Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One (2010) 0.99
Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology (2013) 0.98
Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res (Phila) (2009) 0.96
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol (2010) 0.94
Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells. PLoS One (2011) 0.94
Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res (2013) 0.94
Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis. Am J Pathol (2006) 0.94
Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response. J Nutr Biochem (2012) 0.90
New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.89
Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer. Sci Rep (2014) 0.89
KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer (2009) 0.89
Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract (2011) 0.88
The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol (2010) 0.88
Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol (2009) 0.87
The role of peroxisome proliferator-activated receptor γ in immune responses to enteroaggregative Escherichia coli infection. PLoS One (2013) 0.86
CSF-1 receptor-dependent colon development, homeostasis and inflammatory stress response. PLoS One (2013) 0.84
Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. J Biol Chem (2008) 0.84
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol (2008) 0.83
Food components and the immune system: from tonic agents to allergens. Front Immunol (2013) 0.83
Macrophages, PPARs, and Cancer. PPAR Res (2008) 0.83
The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon. Nutr Rev (2011) 0.82
PPARG binding landscapes in macrophages suggest a genome-wide contribution of PU.1 to divergent PPARG binding in human and mouse. PLoS One (2012) 0.81
PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. Am J Physiol Gastrointest Liver Physiol (2014) 0.81
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am (2010) 0.81
Significance of anti-inflammatory effects of PPARgamma agonists? Gut (2006) 0.80
Activated and inactivated PPARs-γ modulate experimentally induced colitis in rats. Med Sci Monit (2011) 0.80
PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? PPAR Res (2013) 0.80
Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway. PLoS Pathog (2014) 0.79
Animal models of enteroaggregative Escherichia coli infection. Gut Microbes (2013) 0.78
RDH10, RALDH2, and CRABP2 are required components of PPARγ-directed ATRA synthesis and signaling in human dendritic cells. J Lipid Res (2013) 0.78
Adipokines and the role of visceral adipose tissue in inflammatory bowel disease. Ann Gastroenterol (2016) 0.78
NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury. Mucosal Immunol (2016) 0.77
Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. J Inflamm Res (2010) 0.76
Protection by enteral glutamine is mediated by intestinal epithelial cell peroxisome proliferator-activated receptor-γ during intestinal ischemia/reperfusion. Shock (2015) 0.76
Pathophysiological Roles of PPARgamma in Gastrointestinal Epithelial Cells. PPAR Res (2008) 0.76
Intrinsic Defense Mechanisms of the Intestinal Epithelium. Cell Host Microbe (2016) 0.75
Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway. Cell Death Dis (2017) 0.75
Regulation of the mucosal phenotype in dendritic cells by PPARγ: role of tissue microenvironment. J Leukoc Biol (2013) 0.75
Ribosomal alteration-derived signals for cytokine induction in mucosal and systemic inflammation: noncanonical pathways by ribosomal inactivation. Mediators Inflamm (2014) 0.75
Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells. Sci Rep (2017) 0.75
Association of PPAR polymorphisms with cytokine levels in allergic rhinitis. Eur Arch Otorhinolaryngol (2011) 0.75
PPARγ Agonists Attenuate Trigeminal Neuropathic Pain. Clin J Pain (2017) 0.75
The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. Front Immunol (2017) 0.75
Inflammatory bowel disease. N Engl J Med (2002) 21.17
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet (2000) 15.19
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell (1999) 9.74
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol (2003) 8.28
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell (1995) 7.99
Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem (2002) 7.74
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell (1999) 7.56
PPARs and the complex journey to obesity. Nat Med (2004) 7.44
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med (2005) 4.14
Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol (2002) 3.59
Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res (2001) 3.45
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 2.91
Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology (2004) 2.65
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology (2003) 2.65
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
Cytokines in inflammatory bowel disease. World J Surg (1998) 2.30
An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol (2001) 2.26
Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology (2001) 2.19
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res (2003) 2.18
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med (2005) 2.06
Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res (1996) 1.94
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology (2003) 1.91
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem (2000) 1.82
Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev (2005) 1.73
PPAR gamma, 10 years later. Biochimie (2005) 1.60
PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens (2005) 1.55
Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet (2002) 1.50
Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem (2002) 1.48
PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ (2006) 1.47
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis (2005) 1.43
Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology (2001) 1.41
PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis (2004) 1.38
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis (2002) 1.35
Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun (1996) 1.34
Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology (1992) 1.23
Characterization of an interleukin-7-dependent thymic cell line derived from a p53(-/-) mouse. J Immunol Methods (2003) 1.16
PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy (2004) 1.12
Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res (2005) 1.10
Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol (2002) 1.01
Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int J Cancer (2005) 1.01
Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis (2005) 0.99
Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.94
Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep (2004) 0.93
A PPAR-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J(2), inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep (2004) 0.87
Getting fat: two new players in molecular adipogenesis. Cell Metab (2005) 0.85
Is there a role for PPAR gamma in IBD? Yes, no, maybe. Gastroenterology (2003) 0.85
Suppressive effect of 1,4-phenylene diisothiocyanate on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Int J Cancer (2005) 0.78
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol (2001) 8.95
How proteolysis drives the cell cycle. Science (1996) 8.59
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell (1995) 8.34
Anaphase initiation in Saccharomyces cerevisiae is controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. Genes Dev (1996) 8.28
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 7.12
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest (1999) 6.99
P450 genes: structure, evolution, and regulation. Annu Rev Biochem (1987) 6.72
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 6.71
Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science (1995) 6.03
The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev (1996) 5.71
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (1996) 5.14
Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. Cell (2000) 5.10
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol (1993) 4.92
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
Splitting the chromosome: cutting the ties that bind sister chromatids. Science (2000) 4.20
Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem (2000) 4.15
Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology (1979) 4.08
Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell (2000) 4.01
Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol (2001) 3.86
Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem (1998) 3.78
Locus control regions of mammalian beta-globin gene clusters: combining phylogenetic analyses and experimental results to gain functional insights. Gene (1997) 3.77
The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol (1991) 3.73
APC-mediated proteolysis of Ase1 and the morphogenesis of the mitotic spindle. Science (1997) 3.73
Securin is required for chromosomal stability in human cells. Cell (2001) 3.71
Characterization of vertebrate cohesin complexes and their regulation in prophase. J Cell Biol (2000) 3.70
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Exposure to residential electric and magnetic fields and risk of childhood leukemia. Am J Epidemiol (1991) 3.49
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol (2000) 3.46
An NSF-like ATPase, p97, and NSF mediate cisternal regrowth from mitotic Golgi fragments. Cell (1995) 3.40
Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. Transcriptional and post-transcriptional regulation of the rat enzyme. J Biol Chem (1986) 3.39
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell (2001) 3.36
Proportional mortality among vinyl-chloride workers. Lancet (1974) 3.36
Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. Science (2001) 3.35
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem (2000) 3.15
Childhood leukemia and parents' occupational and home exposures. J Natl Cancer Inst (1987) 3.03
The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA (1989) 3.03
Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol (1996) 3.01
Dispersal of first "workers" in social wasps: causes and implications of an alternative reproductive strategy. Proc Natl Acad Sci U S A (1998) 2.96
The P450 gene superfamily: recommended nomenclature. DNA (1987) 2.95
p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. J Virol (1979) 2.94
The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet (1989) 2.90
Effects of maternal smoking during pregnancy and environmental tobacco smoke on asthma and wheezing in children. Am J Respir Crit Care Med (2001) 2.82
Pathogen-specific loss of host resistance in mice lacking the IFN-gamma-inducible gene IGTP. Proc Natl Acad Sci U S A (2000) 2.80
Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet (2001) 2.73
Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature (1999) 2.63
Identification of a cullin homology region in a subunit of the anaphase-promoting complex. Science (1998) 2.61
Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev (2000) 2.58
Occupational exposures of parents of children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group. Cancer Res (1989) 2.55
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons. Proc Natl Acad Sci U S A (1999) 2.54
Activation of the human anaphase-promoting complex by proteins of the CDC20/Fizzy family. Curr Biol (1998) 2.50
Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis (1997) 2.46
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest (1998) 2.42
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol (1992) 2.41
Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol (2001) 2.41
Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol (1986) 2.40
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol (1999) 2.38
The formation of Golgi stacks from vesiculated Golgi membranes requires two distinct fusion events. Cell (1995) 2.35
The occupational and environmental health history. JAMA (1981) 2.34
Scc1/Rad21/Mcd1 is required for sister chromatid cohesion and kinetochore function in vertebrate cells. Dev Cell (2001) 2.30
Steroid induction of mouse mammary tumor virus: effect upon synthesis and degradation of viral RNA. J Virol (1977) 2.26
Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem (1996) 2.25
Lung-specific inactivation of CCAAT/enhancer binding protein alpha causes a pathological pattern characteristic of COPD. Eur Respir J (2009) 2.24
Environmental tobacco smoke and absenteeism related to respiratory illness in schoolchildren. Am J Epidemiol (2003) 2.23
Chronic effect of fire fighting on pulmonary function. N Engl J Med (1974) 2.20
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem (1997) 2.18
DDT and related compounds and risk of pancreatic cancer. J Natl Cancer Inst (1992) 2.16
Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem (1997) 2.15
Job activity and colon cancer risk. Am J Epidemiol (1984) 2.15
Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem (2001) 2.12
Worker-sponsored survey for asbestosis: detection of occupational lung disease without a control group. Arch Environ Health (1973) 2.12
Human dioxin-inducible cytochrome P1-450: complementary DNA and amino acid sequence. Science (1985) 2.11
Genetic support for the evolutionary theory of reproductive transactions in social wasps. Proc Biol Sci (2000) 2.11
Identification of a novel ubiquitin-conjugating enzyme involved in mitotic cyclin degradation. Curr Biol (1996) 2.10
Chlorinated hydrocarbon solvents: substituting our way toward human carcinogenicity. Am J Ind Med (1993) 2.10
Long term freeze storage of Campylobacter pyloridis. J Clin Pathol (1987) 2.08
Early thalamic lesions in patients with sleep-potentiated epileptiform activity. Neurology (2012) 2.08
Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Cancer Res (1999) 2.07
Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. Thorax (2000) 2.06
Acute respiratory effects in workers exposed to low levels of toluene diisocyanate (TDI). Arch Environ Health (1968) 2.04
cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry (1993) 2.03
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science (1989) 2.01
Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem (1998) 2.00
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res (1994) 1.99